I-Mab Biopharma Co., Ltd
http://www.i-mabbiopharma.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From I-Mab Biopharma Co., Ltd
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
Three Chinese Biotechs Bag Late-Stage VC/PE Funding In February
Evopoint, I-Mab Biopharma (Hangzhou) and MAXVAX extended their funding with series E and C rounds, respectively, in February, amid signs that biotech investor sentiment in China may be recovering.
Hidden Dragon? Investors Return To New China Biotech Reality
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Tasgen Biotech
- Third Venture Biopharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice